Advertising

Stryker Corp.

SYK-N

Get Alerts184 watching

NYSE:SYK

273.03
3.08 (1.12%)
Stryker Corporation is a Fortune 500 medical technologies firm based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and ...
More at Wikipedia
SYK Fundamental Data  by TradingView
SYK Chart  by TradingView
Technical Analysis for SYK  by TradingView

Analysis and Opinions about SYK-N

Signal
Opinion
Expert
Chart
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
August 24, 2021
Has long held this. They produce medical devices for hips, knees and spines. The sector fell off during lockdowns due to no or few elective surgeries, however that is rebounding. Also, this is a demographic play as the population ages and needs such surgeries. Also, doctors stay loyal to a brand of medical devices. Trades at 25x earnings and has $3.7 billion in free cash. (Analysts’ price target is $288.43)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
August 24, 2021
Has long held this. They produce medical devices for hips, knees and spines. The sector fell off during lockdowns due to no or few elective surgeries, however that is rebounding. Also, this is a demographic play as the population ages and needs such surgeries. Also, doctors stay loyal to a brand of medical devices. Trades at 25x earnings and has $3.7 billion in free cash. (Analysts’ price target is $288.43)
biotechnology/pharmaceutical
Paul Harris, CFA
Price
$271.205
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
July 22, 2021
(A Top Pick Jul 21/20, Up 37%) Great business. Demographic tailwind. User loyalty. Pandemic surgery slowdown created a backlog that's coming online now. Good free cashflow growth can be used to pay down debt and make acquisitions. Good upside for next several years.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
July 22, 2021
(A Top Pick Jul 21/20, Up 37%) Great business. Demographic tailwind. User loyalty. Pandemic surgery slowdown created a backlog that's coming online now. Good free cashflow growth can be used to pay down debt and make acquisitions. Good upside for next several years.
biotechnology/pharmaceutical
Paul Harris, CFA
Price
$256.870
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
June 17, 2021
(A Top Pick Jun 26/20, Up 50%) Huge backlog of surgeries due to Covid. Really improves quality of life. Terrific brand loyalty. Good demographic play. More upside. Will keep raising dividend, buying back shares, making acquisitions.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
June 17, 2021
(A Top Pick Jun 26/20, Up 50%) Huge backlog of surgeries due to Covid. Really improves quality of life. Terrific brand loyalty. Good demographic play. More upside. Will keep raising dividend, buying back shares, making acquisitions.
biotechnology/pharmaceutical
Paul Harris, CFA
Price
$259.170
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
June 7, 2021
With the opening of elective surgeries, it will start to pickup. The aging population will benefit them. They are head and shoulders above their peers.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
June 7, 2021
With the opening of elective surgeries, it will start to pickup. The aging population will benefit them. They are head and shoulders above their peers.
biotechnology/pharmaceutical
David Driscoll
Price
$249.100
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
May 12, 2021
Rough time, as elective surgeries on hold during Covid. Good growth. Loyal users of products, good demographics. Acquisition of Wright Medical will work out well. Yield is 1.02%. (Analysts’ price target is $270.28)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
May 12, 2021
Rough time, as elective surgeries on hold during Covid. Good growth. Loyal users of products, good demographics. Acquisition of Wright Medical will work out well. Yield is 1.02%. (Analysts’ price target is $270.28)
biotechnology/pharmaceutical
Paul Harris, CFA
Price
$244.760
Owned
Yes
BUY
BUY
Stryker Corp. (SYK-N)
April 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

Show full opinionHide full opinion
Stryker Corp. (SYK-N)
April 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

biotechnology/pharmaceutical
David Burrows
Price
$265.560
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
April 6, 2021
They produce medical devices for hips, knees, hands and ankles. Elective surgeries are coming back after pandemic lockdowns. SYK's medical products reduce medical stays and drug use, which benefits American hospitals and patients. Again demographics are another tailwind. He expects good growth. SYK holds a lot of fresh cash to pay debt and the dividend. (Analysts’ price target is $251.00)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
April 6, 2021
They produce medical devices for hips, knees, hands and ankles. Elective surgeries are coming back after pandemic lockdowns. SYK's medical products reduce medical stays and drug use, which benefits American hospitals and patients. Again demographics are another tailwind. He expects good growth. SYK holds a lot of fresh cash to pay debt and the dividend. (Analysts’ price target is $251.00)
biotechnology/pharmaceutical
Paul Harris, CFA
Price
$248.480
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
March 29, 2021
It has not done that well through the pandemic. Their appliances are used on an elective basis, so their installation got canceled by hospitals. Sales are expected to grow by 19% this year. (Analysts’ price target is $251.00)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
March 29, 2021
It has not done that well through the pandemic. Their appliances are used on an elective basis, so their installation got canceled by hospitals. Sales are expected to grow by 19% this year. (Analysts’ price target is $251.00)
biotechnology/pharmaceutical
Brett Girard, CPA, CA, CFA
Price
$242.030
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
February 11, 2021
(A Top Pick Jan 17/20, Up 16%) Medical devices and robotic-assisted surgery. Elective surgeries have resumed from last quarter.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
February 11, 2021
(A Top Pick Jan 17/20, Up 16%) Medical devices and robotic-assisted surgery. Elective surgeries have resumed from last quarter.
biotechnology/pharmaceutical
Paul MacDonald
Price
$243.700
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
February 11, 2021
Great growth in robotics surgery. Uptick in elective surgery. Stands to benefit from pent-up demand as we return to normal. Likes it short- and medium-term. Yield is 1.03% (Analysts’ price target is $249.12)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
February 11, 2021
Great growth in robotics surgery. Uptick in elective surgery. Stands to benefit from pent-up demand as we return to normal. Likes it short- and medium-term. Yield is 1.03% (Analysts’ price target is $249.12)
biotechnology/pharmaceutical
Paul MacDonald
Price
$243.700
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
December 24, 2020
(A Top Pick Dec 19/19, Up 15%) Medical healthcare. Great demographics, knee, hip, and spine replacements. Important to quality of life. Stock fell in March when elective surgeries were cancelled, but they're coming back. Would buy it here.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
December 24, 2020
(A Top Pick Dec 19/19, Up 15%) Medical healthcare. Great demographics, knee, hip, and spine replacements. Important to quality of life. Stock fell in March when elective surgeries were cancelled, but they're coming back. Would buy it here.
biotechnology/pharmaceutical
Paul Harris, CFA
Price
$237.060
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
October 2, 2020
The gold standard in the industry. They have the best products, sales force and are quick to adapt. They are very innovative. As surgeries start to pick up, their products will see more demand. They are expected to earn $10/share. They are trading at a cheap multiple to normalized earnings. (Analysts’ price target is $214.35)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
October 2, 2020
The gold standard in the industry. They have the best products, sales force and are quick to adapt. They are very innovative. As surgeries start to pick up, their products will see more demand. They are expected to earn $10/share. They are trading at a cheap multiple to normalized earnings. (Analysts’ price target is $214.35)
biotechnology/pharmaceutical
Barry Schwartz
Price
$208.300
Owned
Yes
PAST TOP PICK
PAST TOP PICK
Stryker Corp. (SYK-N)
October 1, 2020
(A Top Pick Jun 05/19, Up 13%) The downside of the pandemic is that elective surgeries were postponed. Knees, hips and other surgical procedures their products are used in were deferred. It is a backlog question. Demographically, more people will need their products.
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
October 1, 2020
(A Top Pick Jun 05/19, Up 13%) The downside of the pandemic is that elective surgeries were postponed. Knees, hips and other surgical procedures their products are used in were deferred. It is a backlog question. Demographically, more people will need their products.
biotechnology/pharmaceutical
Zachary Curry
Price
$206.510
Owned
Yes
TOP PICK
TOP PICK
Stryker Corp. (SYK-N)
September 14, 2020
Medical devices. A lot of elective surgeries were put off but are now coming back. They acquired an ankle and wrist company. There is good international growth. There is a risk in the steep learning curve on these products. (Analysts’ price target is $213.91)
Show full opinionHide full opinion
Stryker Corp. (SYK-N)
September 14, 2020
Medical devices. A lot of elective surgeries were put off but are now coming back. They acquired an ankle and wrist company. There is good international growth. There is a risk in the steep learning curve on these products. (Analysts’ price target is $213.91)
biotechnology/pharmaceutical
Paul Harris, CFA
Price
$206.130
Owned
Yes
PARTIAL BUY
PARTIAL BUY
Stryker Corp. (SYK-N)
August 25, 2020

They're the leader in hips, knees and robotic surgeries. They were hit by COVID because elective surgeries stopped, but those have resumed now. Their revenue growth is 4-5 times higher than peers at 6-7% while peers like Johnson and Johnson were 1-2%. Dividends keep paying. Today is okay to enter this stock, though it's trading at 30x earnings. You can buy a half position now and see what happens.

Show full opinionHide full opinion
Stryker Corp. (SYK-N)
August 25, 2020

They're the leader in hips, knees and robotic surgeries. They were hit by COVID because elective surgeries stopped, but those have resumed now. Their revenue growth is 4-5 times higher than peers at 6-7% while peers like Johnson and Johnson were 1-2%. Dividends keep paying. Today is okay to enter this stock, though it's trading at 30x earnings. You can buy a half position now and see what happens.

biotechnology/pharmaceutical
David Driscoll
Price
$188.510
Owned
Yes
Showing 1 to 15 of 110 entries
Next PageNext Page

Stryker Corp.(SYK-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 7

Stockchase rating for Stryker Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Stryker Corp.(SYK-N) Frequently Asked Questions

What is Stryker Corp. stock symbol?

Stryker Corp. is a American stock, trading under the symbol SYK-N on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK-N

Is Stryker Corp. a buy or a sell?

In the last year, 7 stock analysts published opinions about SYK-N. 7 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Stryker Corp..

Is Stryker Corp. a good investment or a top pick?

Stryker Corp. was recommended as a Top Pick by Paul Harris, CFA on 2021-08-24. Read the latest stock experts ratings for Stryker Corp..

Why is Stryker Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Stryker Corp. worth watching?

7 stock analysts on Stockchase covered Stryker Corp. In the last year. It is a trending stock that is worth watching.

What is Stryker Corp. stock price?

On 2021-09-17, Stryker Corp. (SYK-N) stock closed at a price of $273.03.

© Stockchase Inc.